Depleting T-cell subpopulations in organ transplantation

Transplant International

Volumn 22, Issue 5, 2009, Pages 509-518

  Haudebourg, Thomas ^a   Poirier, Nicolas ^a   Vanhove, Bernard ^a,b  

^a INSERM   (France)

^b HÔTEL DIEU   (France)

Author keywords

Alloreactivity; Homeostasis; T cell depletion; Tolerance; Treg cells

Indexed keywords

ALEMTUZUMAB; ANTIBODY; BASILIXIMAB; CD28 ANTIGEN; CD3 ANTIGEN; CD4 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD45 ANTIGEN; CD45RB ANTIBODY; CD8 ANTIGEN; CYCLOSPORIN A; DACLIZUMAB; HEPARIN; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; RAPAMYCIN; T LYMPHOCYTE RECEPTOR ALPHA CHAIN; T LYMPHOCYTE RECEPTOR BETA CHAIN; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ACUTE GRAFT REJECTION; ALLOIMMUNITY; ANTIGEN EXPRESSION; HOMEOSTASIS; HUMAN; LOW DRUG DOSE; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T CELL DEPLETION; THROMBOEMBOLISM; THROMBOSIS; TRANSPLANTATION TOLERANCE;

EID: 64249122644     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2008.00788.x     Document Type: Review

References (98)

1. Countouriotis A., Moore TB, Sakamoto KM. Cell surface antigen and molecular targeting in the treatment of hematologic malignancies. Stem Cells 2002 20 : 215.
2. Jurianz K, Ziegler S, Garcia-Schüler H, et al. Complement resistance of tumor cells: basal and induced mechanisms. Mol Immunol 1999 36 : 929.
3. Villamor N, Montserrat E, Colomer D. Mechanism of action and resistance to monoclonal antibody therapy. Semin Oncol 2003 30 : 424.
4. Olszewski AJ, Grossbard ML. Empowering targeted therapy: lessons from rituximab. Sci STKE 2004 241 : Pe30.
5. Lowenstein H, Shah A, Chant A, et al. Different mechanisms of Campath-1H-mediated depletion for CD4 and CD8 T cells in peripheral blood. Transpl Int 2006 19 : 927.
6. Hickman SP, Turka LA. Homeostatic T cell proliferation as a barrier to T cell tolerance. Philos Trans R Soc Lond B Biol Sci 2005 360 : 1713.
7. Williams KM, Hakim FT, Gress RE. T cell immune reconstitution following lymphodepletion. Semin Immunol 2007 19 : 318.
8. He G, Kim OS, Thistlethwaite JR, et al. Differential effect of an anti-CD8 monoclonal antibody on rejection of murine intestine and cardiac allografts. Transplant Proc 1999 31 : 1239.
9. Louis S, Audrain M, Cantarovich D, et al. Long-term cell monitoring of kidney recipients after an antilymphocyte globulin induction with and without steroids. Transplantation 2007 83 : 712.
10. Hubbard WJ, Moore JK, Contreras JL, et al. Phenotypic and functional analysis of T-cell recovery after anti-CD3 immunotoxin treatment for tolerance induction in rhesus macaques. Hum Immunol 2001 62 : 479.
11. Pearl JP, Parris J, Hale DA, et al. Immunocompetent T-cells with a memory-like phenotype are the dominant cell type following antibody-mediated T-cell depletion. Am J Transplant 2005 5 : 465.
12. Bonnefoy-Berard N, Revillard JP. Mechanisms of immunosuppression induced by antithymocyte globulins and OKT3. J Heart Lung Transplant 1996 15 : 435.
13. Chung DT, Korn T, Richard J, et al. Anti-thymocyte globulin (ATG) prevents autoimmune encephalomyelitis by expanding myelin antigen-specific Foxp3+ regulatory T cells. Int Immunol 2007 19 : 1003.
14. Lopez M, Clarkson MR, Albin M, et al. A novel mechanism of action for anti-thymocyte globulin: induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006 17 : 2844.
15. Feng X, Kajigaya S, Solomou EE, et al. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood 2008 111 : 3675.
16. Fehr T, Sykes M. Tolerance induction in clinical transplantation. Transpl Immunol 2004 13 : 117.
17. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006 355 : 1967.
18. Boyd K, Dearden CE. Alemtuzumab in the treatment of chronic lymphocytic lymphoma. Expert Rev Anticancer Ther 2008 8 : 525.
19. Reiff A. A review of Campath in autoimmune disease: biologic therapy in the gray zone between immunosuppression and immunoablation. Hematology 2005 10 : 79.
20. Calne R. "Prope" tolerance: induction, lymphocyte depletion with minimal maintenance. Transplantation 2005 80 : 6.
21. Birhiray RE, Shaw G, Guldan S, et al. Phenotypic transformation of CD52(pos) to CD52(neg) leukemic T cells as a mechanism for resistance to CAMPATH-1H. Leukemia 2002 16 : 861.
22. Rowan WC, Hale G, Tite JP, et al. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol 1995 7 : 69.
23. Watanabe T, Masuyama J, Sohma Y, et al. CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T cells. Clin Immunol 2006 120 : 247.
24. Bloom DD, Chang Z, Fechner JH, et al. CD4+CD25+FOXP3+ regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008 8 : 793.
25. Trzonkowski P, Zilvetti M, Chapman S, et al. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 2008 8 : 338.
26. Kirsch BM, Haidinger M, Zeyda M, et al. Alemtuzumab (Campath-1H) induction therapy and dendritic cells: Impact on peripheral dendritic cell repertoire in renal allograft recipients. Transpl Immunol 2006 16 : 254.
27. Janssen O, Wesselborg S, Kabelitz D. Immunosuppression by OKT3 - induction of programmed cell death (apoptosis) as a possible mechanism of action. Transplantation 1992 53 : 233.
28. Carpenter PA, Pavlovic S, Tso JY, et al. Non-Fc receptor-binding humanized anti-CD3 antibodies induce apoptosis of activated human T cells. J Immunol 2000 165 : 6205.
29. Hirsch R, Gress RE, Pluznik DH, et al. Effects of in vivo administration of anti-CD3 monoclonal antibody on T cell function in mice. II. In vivo activation of T cells. J Immunol 1989 142 : 737.
30. Nicolls MR, Aversa GG, Pearce NW, et al. Induction of long-term specific tolerance to allografts in rats by therapy with an anti-CD3-like monoclonal antibody. Transplantation 1993 55 : 459.
31. Chatenoud L. CD3-specific antibody-induced active tolerance: from bench to bedside. Nat Rev Immunol 2003 3 : 123.
32. Smith JA, Tso JY, Clark MR, et al. Nonmitogenic anti-CD3 monoclonal antibodies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 1997 185 : 1413.
33. Armstrong N, Buckley P, Oberley T, et al. Analysis of primate renal allografts after T-cell depletion with anti-CD3-CRM9. Transplantation 1998 66 : 5.
34. Asiedu CK, Goodwin KJ, Balgansuren G, et al. Elevated T regulatory cells in long-term stable transplant tolerance in rhesus macaques induced by anti-CD3 immunotoxin and deoxyspergualin. J Immunol 2005 175 : 8060.
35. Asiedu CK, Goodwin KJ, Balgansuren G, et al. Letter of retraction. J Immunol 2006 177 : 2023.
36. Sido B, Otto G, Zimmermann R, et al. Prolonged allograft survival by the inhibition of costimulatory CD2 signals but not by modulation of CD48 (CD2 ligand) in the rat. Transpl Int 1996 9 (Suppl. 1 S323.
37. Dehoux JP, Talpe S, Dewolf N, et al. Effects on human and nonhuman primate immune response of a new rat anti-CD2 monoclonal antibody. Transplantation 2000 69 : 2622.
38. Shaffer J, Villard J, Means TK, et al. Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. Exp Hematol 2007 35 : 1140.
39. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008 358 : 353.
40. Dufter C, Terness P, Post S, et al. Prolonged rat allograft survival induced by temporary elimination of alpha/beta T cells with monoclonal antibody. Transpl Int 1994 7 (Suppl. 1 S580.
41. Pearson TC, Bushell AR, Darby CR, et al. Lymphocyte changes associated with prolongation of cardiac allograft survival in adult mice using anti-CD4 monoclonal antibody. Clin Exp Immunol 1993 92 : 211.
42. Qin SX, Cobbold S, Benjamin R, et al. Induction of classical transplantation tolerance in the adult. J Exp Med 1989 169 : 779.
43. Flavin T, Shizuru J, Seydel K, et al. Selective T-cell depletion with Ox-38 anti-CD4 monoclonal antibody prevents cardiac allograft rejection in rats. J Heart Transpl 1989 9 : 482.
44. Bushell A, Morris PJ, Wood KJ. Transplantation tolerance induced by antigen pretreatment and depleting anti-CD4 antibody depends on CD4+ T cell regulation during the induction phase of the response. Eur J Immunol 1995 25 : 2643.
45. Arima T, Lehmann M, Flye MW. Induction of donor specific transplantation tolerance to cardiac allografts following treatment with nondepleting (RIB 5/2) or depleting (OX-38) anti-CD4 mAb plus intrathymic or intravenous donor alloantigen. Transplantation 1997 63 : 284.
46. Motoyama K, Kamei T, Arima T, et al. Pretransplant intrathymic inoculation of donor antigen combined with FK506 treatment: prolongation of survival of cardiac, but not renal, allografts in rats. World J Surg 1997 : 19 : 299.
47. Watson CJ, Cobbold SP, Davies HS, et al. Immunosuppression of canine renal allograft recipients by CD4 and CD8 monoclonal antibodies. Tissue Antigens 1994 43 : 155.
48. Mourad GJ, Preffer FI, Wee SL, et al. Humanized IgG1 and IgG4 anti-CD4 monoclonal antibodies: effects on lymphocytes in the blood, lymph nodes, and renal allografts in cynomolgus monkeys. Transplantation 1998 65 : 632.
49. Ninova DI, Ferguson DM, Wettstein PJ, et al. Liver allograft rejection in rats depleted of CD8+ cells. Transpl Int 1996 9 : 499.
50. Seydel K, Shizuru J, Grossman D, et al. Anti-CD8 abrogates effect of anti-CD4-mediated islet allograft survival in rat model. Diabetes 1991 40 : 1430.
51. Lu X, Borel JF. Requirement of CD4 cells for induction and maintenance of unresponsiveness in islet xenografted mice. Xenotransplantation 1998 5 : 207.
52. Mottram PL, Murray-Segal LJ, Han W, et al. Transgenic anti-CD4 monoclonal antibody secretion by mouse segmental pancreas allografts promotes long term survival. Transpl Immunol 2000 8 : 203.
53. Mandel TE, Dillon H, Koulmanda M. The effect of a depleting anti-CD4 monoclonal antibody on T cells and fetal pig islet xenograft survival in various strains of mice. Transpl Immunol 1995 3 : 265.
54. Makhlouf L, Grey ST, Dong V, et al. Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice. Transplantation 2004 77 : 990.
55. Bishop DK, Li W, Chan SY, et al. Helper T lymphocyte unresponsiveness to cardiac allografts following transient depletion of CD4-positive cells. Implications for cellular and humoral responses. Transplantation 1994 58 : 576.
56. Uehara S, Chase CM, Colvin RB, et al. T-cell depletion eliminates the development of cardiac allograft vasculopathy in mice rendered tolerant by the induction of mixed chimerism. Transplant Proc 2006 38 : 3169.
57. Yi H, Zhen Y, Zeng C, et al. Depleting anti-CD4 monoclonal antibody (GK1.5) treatment: influence on regulatory CD4+CD25+Foxp3+ T cells in mice. Transplantation 2008 85 : 1167.
58. Schenk AD, Nozaki T, Rabant M, et al. Donor-Reactive CD8 Memory T Cells Infiltrate Cardiac Allografts Within 24-h Posttransplant in Naive Recipients. Am J Transplant 2008 85 : 1167.
59. Koyama I, Nadazdin O, Boskovic S, et al. Depletion of CD8 memory T cells for induction of tolerance of a previously transplanted kidney allograft. Am J Transplant 2007 7 : 1055.
60. Allan JS, Choo JK, Vesga L, et al. Cardiac allograft vasculopathy is abrogated by anti-CD8 monoclonal antibody therapy. Ann Thorac Surg 1997 64 : 1019.
61. Chan SY, DeBruyne LA, Goodman RE, et al. In vivo depletion of CD8+ T cells results in Th2 cytokine production and alternate mechanisms of allograft rejection. Transplantation 1995 59 : 1155.
62. Forbes RD, Zheng SX, Gomersall M, et al. Evidence that recipient CD8+ T cell depletion does not alter development of chronic vascular rejection in a rat heart allograft model. Transplantation 1994 57 : 1238.
63. Wee SL, Colvin RB, Phelan JM, et al. Fc-receptor for mouse IgG1 (Fc gamma RII) and antibody-mediated cell clearance in patients treated with Leu2a antibody. Transplantation 1989 48 : 1012.
64. Lin C, Hünig T. Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 2003 33 : 626.
65. Haspot F, Villemain F, Laflamme G, et al. Differential effect of CD28 versus B7 blockade on direct pathway of allorecognition and self-restricted responses. Blood 2002 99 : 2228.
66. Bryl E, Vallejo AN, Weyand CM, et al. Down-regulation of CD28 expression by TNF-alpha. J Immunol 2001 167 : 3231.
67. Yu X, Albert MH, Martin PJ, et al. CD28 ligation induces transplantation tolerance by IFN-gamma-dependent depletion of T cells that recognize alloantigens. J Clin Invest 2004 113 : 1624.
68. Golovina TN, Mikheeva T, Suhoski MM, et al. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol 2008 181 : 2855.
69. Ito T, Hanabuchi S, Wang Y, et al. Two functional subsets of FOXP3+ regulatory T cells in human thymus and periphery. Immunity 2008 28 : 870.
70. Liu Z, Tugulea S, Cortesini R, et al. Specific suppression of T helper alloreactivity by allo-MHC class I-restricted CD8+CD28- T cells. Int Immunol 1998 10 : 775.
71. Cortesini R, Suciu-Foca N. The concept of "partial" clinical tolerance. Transpl Immunol 2004 13 : 101.
72. St Clair EW. The calm after the cytokine storm: lessons from the TGN1412 trial. J Clin Invest 2008 118 : 1344.
73. Schraven B, Kalinke U. CD28 superagonists: what makes the difference in humans? Immunity 2008 28 : 591.
74. Thomas-Vaslin V, Bellier B, Cohen JL, et al. Prolonged allograft survival through conditional and specific ablation of alloreactive T cells expressing a suicide gene. Transplantation 2000 69 : 2154.
75. Kirk AD, Burkly LC, Batty DS, et al. Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. Nat Med 1999 5 : 686.
76. Monk NJ, Hargreaves REG, Marsh JE, et al. Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade. Nat Med 2003 9 : 1275.
77. Cho CS, Burkly LC, Fechner JH, et al. Successful conversion from conventional immunosuppression to anti-CD154 monoclonal antibody costimulatory molecule blockade in rhesus renal allograft recipients. Transplantation 2001 72 : 587.
78. Haudebourg T, Dugast A, Coulon F, et al. Depletion of LAG-3 positive cells in cardiac allograft reveals their role in rejection and tolerance. Transplantation 2007 84 : 1500.
79. Maçon-Lemaître L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 2005 115 : 170.
80. Huang C, Workman CJ, Flies D, et al. Role of LAG-3 in regulatory T cells. Immunity 2004 21 : 503.
81. Waldmann TA. The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes. Science 1986 232 : 727.
82. Kuttler B, Kauert C, Wanka H, et al. Temporary anti-CD25/CsA therapy induces a CD4+ T-cell-mediated tolerance in BB/OK rats. J Autoimmun 1996 9 : 321.
83. Strom TB, Kelley VR, Woodworth TG, et al. Interleukin-2 receptor-directed immunosuppressive therapies: antibody- or cytokine-based targeting molecules. Immunol Rev 1992 12 : 9131.
84. Li W, Carper K, Liang Y, et al. Anti-CD25 mAb administration prevents spontaneous liver transplant tolerance. Transplant Proc 2006 38 : 3207.
85. Benghiat FS, Graca L, Braun MY, et al. Critical influence of natural regulatory CD25+ T cells on the fate of allografts in the absence of immunosuppression. Transplantation 2005 79 : 648.
86. Kreijveld E, Koenen HJPM, Klasen IS, et al. Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 2007 7 : 249.
87. Vlad G, Ho EK, Vasilescu ER, et al. Anti-CD25 treatment and FOXP3-positive regulatory T cells in heart transplantation. Transpl Immunol 2007 18 : 13.
88. Bielekova B, Catalfamo M, Reichert-Scrivner S, et al. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis. Proc Natl Acad Sci USA 2006 103 : 5941.
89. Rothstein DM, Yamada A, Schlossman SF, et al. Cyclic regulation of CD45 isoform expression in a long term human CD4+CD45RA+ T cell line. J Immunol 1991 146 : 1175.
90. Davies JD, O'Connor E, Hall D, et al. CD4+ CD45RB low-density cells from untreated mice prevent acute allograft rejection. J Immunol 1999 163 : 5353.
91. Luke PPW, Deng JP, Lian D, et al. Prolongation of allograft survival by administration of anti-CD45RB monoclonal antibody is due to alteration of CD45RBhi: CD45RBlo T-cell proportions. Am J Transplant 2006 6 : 2023.
92. Leach MW, Bean AG, Mauze S, et al. Inflammatory bowel disease in C.B-17 scid mice reconstituted with the CD45RBhigh subset of CD4+ T cells. Am J Pathol 1996 148 : 1503.
93. Lazarovits AI, Poppema S, Zhang Z, et al. Prevention and reversal of renal allograft rejection by antibody against CD45RB. Nature 1996 380 : 717.
94. Gajewski TF, Qian D, Fields P, et al. Anergic T-lymphocyte clones have altered inositol phosphate, calcium, and tyrosine kinase signaling pathways. Proc Natl Acad Sci USA 1994 91 : 38.
95. Basadonna GP, Auersvald L, Khuong CQ, et al. Antibody-mediated targeting of CD45 isoforms: a novel immunotherapeutic strategy. Proc Natl Acad Sci USA 1998 95 : 3821.
96. Tchilian EZ, Beverley PCL. CD45 in memory and disease. Arch Immunol Ther Exp (Warsz) 2002 50 : 85.
97. Dutton RW, Bradley LM, Swain SL. T cell memory. Annu Rev Immunol 1998 16 : 201.
98. Chen G, Luke PPW, Yang H, et al. Anti-CD45RB monoclonal antibody prolongs renal allograft survival in cynomolgus monkeys. Am J Transplant 2007 7 : 27.